Abstract
The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Keywords: Neuroprotective, Parkinson, genetics
Current Neuropharmacology
Title: Neuroprotective Strategies for Parkinsons Disease
Volume: 2 Issue: 3
Author(s): Ippolita Cantuti-Castelvetri and David G. Standaert
Affiliation:
Keywords: Neuroprotective, Parkinson, genetics
Abstract: The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Export Options
About this article
Cite this article as:
Cantuti-Castelvetri Ippolita and Standaert G. David, Neuroprotective Strategies for Parkinsons Disease, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359585
DOI https://dx.doi.org/10.2174/1570159043359585 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Selective α7 Nicotinic Acetylcholine Receptor Ligands
Current Medicinal Chemistry Oxidative Stress and Neurodegenerative Diseases: A Neurotrophic Approach
Current Drug Targets New Improved Drug Delivery Technologies for Pentacyclic Triterpenes: A Review
Protein & Peptide Letters Biochemical Characterization of Apoptotic Cleavage of KH-Type Splicing Regulatory Protein (KSRP) / Far Upstream Element-Binding Protein 2 (FBP2)
Protein & Peptide Letters Dopamine D1 Receptors, Regulation of Gene Expression in the Brain, and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
Current Medicinal Chemistry Dimethyl-Carbamic Acid 2,3-Bis-Dimethylcarbamoyloxy-6-(4-Ethyl-Piperazine- 1-Carbonyl)-Phenyl Ester: A Novel Multi-Target Therapeutic Approach to Neuroprotection
Medicinal Chemistry Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-Propylpentanamide, a Valproic Acid Aryl Derivative with Activity Against HeLa Cells
Current Molecular Pharmacology The Concept of Dysregulated Signal Transduction and Gene Expression in the Pathophysiology of Mood Disorders
Current Psychiatry Reviews Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Iron Oxide Nanoparticle Platform for Biomedical Applications
Current Medicinal Chemistry Therapeutic Potential of Hammerhead Ribozymes in the Treatment of Hyper-Proliferative Diseases
Current Pharmaceutical Biotechnology HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Neuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration
Current Molecular Medicine A Proteomic Analysis of Human Uterine Myoma
Current Protein & Peptide Science Nongenomic Actions of Thyroid Hormones: From Basic Research to Clinical Applications. An Update
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cancer Vaccines: Emphasis on Pediatric Cancers
Current Pharmaceutical Design Alternative Splice Variants of Survivin as Potential Targets in Cancer
Current Drug Discovery Technologies Functions of S100 Proteins
Current Molecular Medicine